158 related articles for article (PubMed ID: 2843088)
1. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
Moosdeen F; Williams JD; Yamabe S
Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
3. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
Simonet M; Moittie D; Philippon A; Descamps P; Veron M
J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
[No Abstract] [Full Text] [Related]
4. Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
Piddock LJ; Traynor EA; Griggs DJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):364-71. PubMed ID: 1396760
[TBL] [Abstract][Full Text] [Related]
5. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff SC; Jacobs MR; Johenning S; Yamabe S
Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
7. Effect of a beta-lactamase inhibitor, tazobactam, on growth and penicillin-binding proteins of Borrelia burgdorferi.
Urban C; Rahal JJ; Luft B
FEMS Microbiol Lett; 1991 Jul; 66(1):113-6. PubMed ID: 1657694
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
10. Sulbactam: biochemical factors involved in its synergy with ampicillin.
Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
[TBL] [Abstract][Full Text] [Related]
11. Evolution of beta-lactamase inhibitors.
Rolinson GN
Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
[TBL] [Abstract][Full Text] [Related]
12. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus.
Fasola EL; Fasching CE; Peterson LR
J Lab Clin Med; 1995 Feb; 125(2):200-11. PubMed ID: 7844469
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
14. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin.
Yokota T
APMIS Suppl; 1989; 5():9-16. PubMed ID: 2786726
[TBL] [Abstract][Full Text] [Related]
16. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
Moosdeen F; Keeble J; Williams JD
Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
[TBL] [Abstract][Full Text] [Related]
17. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
Hedberg M; Lindqvist L; Tunér K; Nord CE
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
[TBL] [Abstract][Full Text] [Related]
19. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
20. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
